Physician profile
Thomas Wayne Day
NPI 1356410195
$16,406.71
in general payments reported to CMS, 2019-2025
40 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $1,211 · 2021: $2,400 · 2022: $3,048 · 2023: $3,731 · 2024: $3,414 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,144 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,143.51 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,805.26 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,718.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,553.45 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,428.98 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Lilly USA, LLC | $982.46 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $958.48 | 2019-2025 | Tremfya |
| Amgen INC. | $882.88 | 2019-2024 | Otezla |
| Ucb, INC. | $769.00 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $582.57 | 2020-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $571.81 | 2022-2024 | Sotyktu |
| Incyte Corporation | $568.38 | 2021-2025 | Opzelura |
| Genzyme Corporation | $389.88 | 2019-2025 | |
| Pfizer INC. | $372.76 | 2019-2024 | |
| Biofrontera INC. | $240.27 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $231.23 | 2019-2025 | Nemluvio, Aklief |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $195.16 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.20 | 2023-2024 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.22 | 2019-2024 | Arazlo, Jublia |
| Kerecis Limited | $110.04 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Genentech USA, INC. | $97.39 | 2019-2022 | |
| Almirall LLC | $80.96 | 2019-2023 | Klisyri |
| Organon LLC | $77.12 | 2023-2024 | Hadlima |
| Fresenius Kabi USA, LLC | $54.32 | 2023 | |
| Stemline Therapeutics INC. | $41.08 | 2021-2022 | |
| Kyowa Kirin, INC. | $41.01 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $37.82 | 2019 | |
| Verrica Pharmaceuticals INC. | $34.63 | 2023-2024 | Ycanth |
| Convatec INC. | $34.12 | 2025 | |
| Mayne Pharma Commercial LLC | $33.86 | 2022 | |
| Ani Pharmaceuticals, INC. | $30.80 | 2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $27.02 | 2019 | |
| Botanix Sb INC | $23.62 | 2025 | Sofdra |
| Dermira, INC. | $22.49 | 2019 | |
| Arcutis Biotherapeutics, INC. | $21.04 | 2023 | |
| Vyne Pharmaceuticals INC. | $19.77 | 2021 | |
| Merz North America, INC. | $18.63 | 2019 | |
| Dermavant Sciences, INC. | $18.48 | 2023 | Vtama |
| Mission Pharmacal Company | $14.91 | 2019 | |
| Paratek Pharmaceuticals, INC. | $14.35 | 2024 | Nuzyra |
| Strata Skin Sciences, INC. | $14.23 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.